デフォルト表紙
市場調査レポート
商品コード
1807147

末梢血単核球市場- 世界の産業規模、シェア、動向、機会、予測、製品別、用途別、技術別、供給源別、地域別、競合別、2020-2030年

Peripheral Blood Mononuclear Cells Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Application, By Techniques, By Source, By Region and Competition, 2020-2030F

出版日
ページ情報
英文 185 Pages
納期
2～3営業日
カスタマイズ可能
末梢血単核球市場- 世界の産業規模、シェア、動向、機会、予測、製品別、用途別、技術別、供給源別、地域別、競合別、2020-2030年
出版日: 2025年08月31日
発行: TechSci Research
ページ情報: 英文 185 Pages
納期: 2～3営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 目次
概要

末梢血単核球の世界市場は、2024年には2億8,089万米ドルと評価され、予測期間中のCAGRは10.02%で、2030年には4億9,602万米ドルに達すると予測されています。

末梢血単核球の世界市場は、細胞療法数の増加率、毒性試験のための研究開発需要の高さ、製品の新規安定開発を担う化合物の反応メカニズムによって、大きな成長を遂げています。例えば、2023年6月にNational Library of Medicineに掲載された研究では、トリパノソーマ・クルージ（Trypanosoma cruzi）のコロンビア株（Col）に試験管内で感染させ、ベンゾニダゾールで処理した末梢血単核球（PBMC）の免疫反応を評価しています。

市場概要
予測期間 2026-2030
市場規模：2024年 2億8,089万米ドル
市場規模：2030年 4億9,602万米ドル
CAGR：2025年～2030年 10.02%
急成長セグメント 免疫学
最大市場 北米

市場促進要因

政府資金による細胞療法と免疫学研究

主な市場課題

規制および品質コンプライアンスの複雑さ

主要市場動向

ワクチン開発と免疫モニタリングにおける役割の拡大

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19が世界の末梢血単核球市場に与える影響

第5章 顧客の声

第6章 世界の末梢血単核球市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 製品別（凍結保存または冷凍PBMC、培養または新鮮PBMC、および末梢血単核細胞分離および生存率キット）
    • 用途別（免疫学、感染症、血液学、その他）
    • 技術別（密度勾配遠心分離法および白血球除去法）
    • 発生源別（人間と動物）
    • 地域別（北米、欧州、アジア太平洋、南米、中東・アフリカ）
    • 企業別（2024）
  • 市場マップ
    • 製品別
    • 用途別
    • 技術別
    • ソース別
    • 地域別

第7章 北米の末梢血単核球市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • カナダ
    • メキシコ

第8章 欧州の末梢血単核球市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン

第9章 アジア太平洋地域の末梢血単核球市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋地域：国別分析
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア

第10章 南米の末梢血単核球市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第11章 中東・アフリカの末梢血単核球市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • アラブ首長国連邦
    • サウジアラビア
    • 南アフリカ

第12章 市場力学

  • 促進要因
  • 課題

第13章 市場動向と発展

  • 合併と買収
  • 製品上市
  • 最近の動向

第14章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威/サービス

第15章 SWOT分析：世界の末梢血単核球市場

第16章 臨床試験分析

第17章 競合情勢

  • Charles River Laboratories International, Inc.
  • Lonza Group AG
  • Corning Inc.
  • Bio-Rad Laboratories Inc.
  • ABCAM
  • Biolegend Inc.
  • ZEN-Bio Inc.
  • DAPCEL, Inc.
  • Creative Bioarray
  • iXCells Biotechnologies USA, LLC

第18章 戦略的提言

第19章 調査会社について・免責事項

目次
Product Code: 4561

Global Peripheral Blood Mononuclear Cells Market was valued at USD 280.89 million in 2024 and is expected to reach USD 496.02 million by 2030 with a CAGR of 10.02% during the forecast period. The global market for Peripheral Blood Mononuclear Cells is experiencing significant growth, driven by the rising rate in number of cell therapies, high demand of research and development for toxicology testing and reaction mechanism of the compound responsible for new and stable development of products. For instance, in June 2023, a study published in National Library of Medicine, it assessed the immune response of peripheral blood mononuclear cells (PBMC) that were infected in vitro with the Colombian strain (Col) of Trypanosoma cruzi and treated with Benzonidazole.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 280.89 Million
Market Size 2030USD 496.02 Million
CAGR 2025-203010.02%
Fastest Growing SegmentImmunology
Largest MarketNorth America

Key Market Drivers

Government-Funded Cell Therapy and Immunology Research

Governments worldwide are significantly increasing investments in cell and gene therapy, where PBMCs play a critical role. In the U.S., the National Institutes of Health (NIH) continues to back programs-such as immuno-oncology and vaccine research-that rely heavily on PBMC-based assays to characterize immune responses before and after experimental treatments. NIH-funded vaccine programs studying T-cell immunity routinely isolate PBMCs from donors to quantify immunogenicity in clinical testing. Similarly, in Europe, the Innovative Medicines Initiative (IMI)-a €2 billion public-private partnership co-funded by the European Commission-supports drug development platforms that use PBMC-based biomarker identification and immune monitoring in early-phase clinical trials. This large-scale public-sector support for PBMC-integrated therapeutics research underlines PBMCs' indispensable role in translational medicine and offers a robust, policy-backed driver for market expansion.

Key Market Challenges

Regulatory and Quality Compliance Complexity

A significant challenge arises from the stringent and fragmented regulatory frameworks governing PBMC collection, processing, and distribution across jurisdictions. In the European Union, PBMC isolation facilities must conform to EU Tissue and Cells Directives (EUTCD) as well as national regulatory agency audits (e.g., Germany's Paul-Ehrlich-Institut), with repeat compliance checks and data privacy enforcement under GDPR-violations can incur fines exceeding €20 million. In China, PBMC processing kits are treated as Class III medical devices requiring clinical validation, and export of PBMC samples with human genetic information is restricted under the 2021 Biosecurity Law, mandating dual approvals from NMPA and the Ministry of Commerce. These variable, complex regulations raise costs for cross-border research and discourage adoption in regions without harmonized oversight, inhibiting global standardization and scalable PBMC usage.

Key Market Trends

Expanding Role in Vaccine Development and Immuno-Monitoring

A rapidly emerging trend is the expanded application of PBMCs for vaccine research and immunogenicity evaluation, especially in government-backed vaccine rollouts and pandemic preparedness. PBMCs offer critical insight into T-cell responses, cytokine profiles, and durability of immune memory. Governments funding large-scale vaccine trials-for diseases like COVID-19, malaria, tuberculosis-routinely incorporate PBMC-based assays into protocols to evaluate safety and immune efficacy. This creates predictable public-sector demand for standardized PBMC isolation, storage, and testing services, accelerating market growth tied to national immunization programs.

Key Market Players

  • Charles River Laboratories International, Inc.
  • Lonza Group AG
  • Corning Inc.
  • Bio-Rad Laboratories Inc.
  • ABCAM
  • Biolegend Inc.
  • ZEN-Bio Inc.
  • DAPCEL, Inc.
  • Creative Bioarray
  • iXCells Biotechnologies USA, LLC

Report Scope:

In this report, the Global Peripheral Blood Mononuclear Cells Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Peripheral Blood Mononuclear Cells Market, By Product:

  • Cryopreserved or Frozen PBMC
  • Cultured or Fresh PBMC
  • Peripheral Blood Mononuclear Cell Isolation & Viability Kits

Peripheral Blood Mononuclear Cells Market, By Application:

  • Immunology
  • Infectious Disease
  • Hematology
  • Others

Peripheral Blood Mononuclear Cells Market, By Technique:

  • Density Gradient Centrifugation Process
  • Leukapheresis

Peripheral Blood Mononuclear Cells Market, By Source:

  • Human
  • Animals

Peripheral Blood Mononuclear Cells Market, By Region:

  • North America
    • United States
    • Mexico
    • Canada
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Japan
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Peripheral Blood Mononuclear Cells Market.

Available Customizations:

Global Peripheral Blood Mononuclear Cells Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Peripheral Blood Mononuclear Cells Market

5. Voice of Customer

6. Global Peripheral Blood Mononuclear Cells Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product (Cryopreserved or Frozen PBMC, Cultured or Fresh PBMC and Peripheral Blood Mononuclear Cell Isolation & Viability Kits)
    • 6.2.2. By Application (Immunology, Infectious Disease, Hematology and Others)
    • 6.2.3. By Technique (Density Gradient Centrifugation Process and Leukapheresis)
    • 6.2.4. By Source (Human and Animals)
    • 6.2.5. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
    • 6.2.6. By Company (2024)
  • 6.3. Market Map
    • 6.3.1. By Product
    • 6.3.2. By Application
    • 6.3.3. By Technique
    • 6.3.4. By Source
    • 6.3.5. By Region

7. North America Peripheral Blood Mononuclear Cells Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Application
    • 7.2.3. By Technique
    • 7.2.4. By Source
    • 7.2.5. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Peripheral Blood Mononuclear Cells Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Technique
        • 7.3.1.2.4. By Source
    • 7.3.2. Canada Peripheral Blood Mononuclear Cells Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Technique
        • 7.3.2.2.4. By Source
    • 7.3.3. Mexico Peripheral Blood Mononuclear Cells Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Technique
        • 7.3.3.2.4. By Source

8. Europe Peripheral Blood Mononuclear Cells Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Application
    • 8.2.3. By Technique
    • 8.2.4. By Source
    • 8.2.5. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. Germany Peripheral Blood Mononuclear Cells Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Technique
        • 8.3.1.2.4. By Source
    • 8.3.2. France Peripheral Blood Mononuclear Cells Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Technique
        • 8.3.2.2.4. By Source
    • 8.3.3. United Kingdom Peripheral Blood Mononuclear Cells Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Technique
        • 8.3.3.2.4. By Source
    • 8.3.4. Italy Peripheral Blood Mononuclear Cells Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By Technique
        • 8.3.4.2.4. By Source
    • 8.3.5. Spain Peripheral Blood Mononuclear Cells Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By Technique
        • 8.3.5.2.4. By Source

9. Asia-Pacific Peripheral Blood Mononuclear Cells Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Application
    • 9.2.3. By Technique
    • 9.2.4. By Source
    • 9.2.5. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Peripheral Blood Mononuclear Cells Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Technique
        • 9.3.1.2.4. By Source
    • 9.3.2. Japan Peripheral Blood Mononuclear Cells Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Technique
        • 9.3.2.2.4. By Source
    • 9.3.3. India Peripheral Blood Mononuclear Cells Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Technique
        • 9.3.3.2.4. By Source
    • 9.3.4. South Korea Peripheral Blood Mononuclear Cells Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Product
        • 9.3.4.2.2. By Application
        • 9.3.4.2.3. By Technique
        • 9.3.4.2.4. By Source
    • 9.3.5. Australia Peripheral Blood Mononuclear Cells Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Product
        • 9.3.5.2.2. By Application
        • 9.3.5.2.3. By Technique
        • 9.3.5.2.4. By Source

10. South America Peripheral Blood Mononuclear Cells Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Application
    • 10.2.3. By Technique
    • 10.2.4. By Source
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Peripheral Blood Mononuclear Cells Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Technique
        • 10.3.1.2.4. By Source
    • 10.3.2. Argentina Peripheral Blood Mononuclear Cells Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Technique
        • 10.3.2.2.4. By Source
    • 10.3.3. Colombia Peripheral Blood Mononuclear Cells Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Technique
        • 10.3.3.2.4. By Source

11. Middle East and Africa Peripheral Blood Mononuclear Cells Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Product
    • 11.2.2. By Application
    • 11.2.3. By Technique
    • 11.2.4. By Source
    • 11.2.5. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. UAE Peripheral Blood Mononuclear Cells Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Product
        • 11.3.1.2.2. By Application
        • 11.3.1.2.3. By Technique
        • 11.3.1.2.4. By Source
    • 11.3.2. Saudi Arabia Peripheral Blood Mononuclear Cells Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Product
        • 11.3.2.2.2. By Application
        • 11.3.2.2.3. By Technique
        • 11.3.2.2.4. By Source
    • 11.3.3. South Africa Peripheral Blood Mononuclear Cells Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Product
        • 11.3.3.2.2. By Application
        • 11.3.3.2.3. By Technique
        • 11.3.3.2.4. By Source

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Merger & Acquisition (If Any)
  • 13.2. Product Launches (If Any)
  • 13.3. Recent Developments

14. Porters Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products/Services

15. SWOT Analysis: Global Peripheral Blood Mononuclear Cells Market

16. Clinical Trial Analysis

  • 16.1. Ongoing Clinical Trials
  • 16.2. Completed Clinical Trials
  • 16.3. Terminated Clinical Trials
  • 16.4. Breakdown of Pipeline, By Development Phase
  • 16.5. Breakdown of Pipeline, By Status
  • 16.6. Breakdown of Pipeline, By Study Type
  • 16.7. Breakdown of Pipeline, By Region
  • 16.8. Clinical Trials Heat Map

17. Competitive Landscape

  • 17.1. Charles River Laboratories International, Inc.
    • 17.1.1. Business Overview
    • 17.1.2. Company Snapshot
    • 17.1.3. Products & Services
    • 17.1.4. Financials (As Reported)
    • 17.1.5. Recent Developments
    • 17.1.6. Key Personnel Details
    • 17.1.7. SWOT Analysis
  • 17.2. Lonza Group AG
  • 17.3. Corning Inc.
  • 17.4. Bio-Rad Laboratories Inc.
  • 17.5. ABCAM
  • 17.6. Biolegend Inc.
  • 17.7. ZEN-Bio Inc.
  • 17.8. DAPCEL, Inc.
  • 17.9. Creative Bioarray
  • 17.10. iXCells Biotechnologies USA, LLC

18. Strategic Recommendations

19. About Us & Disclaimer